Home  /  Resource Library  /  Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD agent, +/- rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD agent, +/- rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

ASH 2025